Physician profile

Kamran Muhammad

Interventional Cardiology · Tulsa, OK

NPI 1164406906

$1,361,830.64

in general payments reported to CMS, 2019-2025

26 companies · $340K in 2025

The $340K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$387,162.50
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$214,115.63
Travel and Lodging$112,170.61
Food and Beverage$11,691.16
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$8,625.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Edwards Lifesciences Corporation $1,019,030.51 2019-2025 Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve
Medtronic, INC. $235,151.04 2021-2025 Corevalve Evolut R
Medtronic Vascular, INC. $61,260.87 2019-2020
Abbott Laboratories $32,779.85 2019-2025 Navitor, Triclip, Mitraclip
Boston Scientific Corporation $5,204.88 2019-2025 Vitalyst, Watchman Flx
Ancora Heart, INC. $4,596.46 2022-2025 Accucinch
Abiomed $1,410.27 2019-2025 Impella
Jenavalve Technology, INC. $1,349.81 2019
Biocardia, INC. $315.65 2019
Heartflow, INC. $121.42 2019
Angiodynamics, INC. $92.57 2019
Silk Road Medical, INC. $77.64 2023 Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System
Janssen Pharmaceuticals, INC $66.83 2022
Cardiva Medical, INC. $48.83 2022
E.R. Squibb & Sons, L.L.C. $48.28 2019-2022
Show all 26 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $44.28 2020-2022
Cardiac Dimensions, INC. $40.85 2025
Pfizer INC. $37.26 2023-2025
Chiesi USA, INC. $31.97 2025 Cleviprex, Kengreal
Surmodics, INC. $26.94 2025 Pounce Venous Thrombectomy System, Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy
Philips North America LLC $17.83 2022
Hologic Sales and Service, LLC $17.41 2023 Coolseal Generator
Merck Sharp & Dohme LLC $16.72 2024
Scpharmaceuticals INC. $16.65 2024
B. Braun Interventional Systems INC. $13.51 2019
Inari Medical, INC. $12.31 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$16.57 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kamran Muhammad

$1,361,830.64

in general payments reported 2019-2025

Years
2019-2025
Top company
Edwards Lifesciences Corporation
Context
The $340K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/234209/kamran-muhammad

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.